South Korean drugmakers lift R&D spending 20.9% ahead of generic price cuts
AI Summary- South Korean drugmakers are increasing R&D investment before phased generic-price cuts begin next year.
- 560.7 billion won was spent on R&D during the first half of this year.
- Whanin Pharm and Korea Pharma reduced first-half R&D spending as smaller firms cut costs.